摘要
目的探讨CA125和TAM联合检测对妇科恶性肿瘤的诊断应用价值。方法采集妇科恶性肿瘤患者40例、妇科良性肿瘤患者40例、正常对照40例的血清样品,分别采用电化学发光法和化学比色法测定CA125和TAM的含量比较分析。结果妇科恶性肿瘤患者血清CA125阳性率77.5%,显著高于良性肿瘤组15%与健康对照组5%,差异有统计学意义(P<0.05);妇科恶性肿瘤患者TAM的阳性率为80%,高于良性肿瘤组17.5%和健康对照组2.5%,差异有统计学意义(P<0.05);CA125和TAM联合检测的阳性率是97.5%,显著高于CA125和TAM单独检测的阳性率77.5%与80%,差异有统计学意义(P<0.05)。结论血清CA125和TAM联合检测不仅可以提高妇科恶性肿瘤的阳性诊断率,而且对妇科肿瘤良恶性的辅助诊断及鉴别诊断具有一定临床应用价值。
Objective To evaluate the diagnostic value of CA125 and TAM joint detection of gynecological malignancies. Methods Collected 40 cases of patients with gynecologic malignancies,gynecological benign tumors of 40 patients,40 cases of normal control serum samples,respectively,using the electrochemiluminescence method and chemical colorimetric determination of CA125 and TAM content analysis. Results Gynecological malignancies in patients with serum CA125 positive rate of 77. 5% ,significantly higher than the benign group 15% and 5% of the healthy control group,the difference was statistically significant （ P 〈0. 05） ; patients with gynecologic malignancies TAM positive rate of 80% 17. 5% and the healthy control group,2. 5% higher than the benign group,the difference was statistically significant （ P 〈0. 05） ; the CA125 and TAM detection positive rate is 97. 5% ,significantly higher than the rate of CA125,and TAM separate testing positive 77. 5 % and 80% ,the difference was statistically significant （ P 〈0. 05） . Conclusion Serum CA125 and TAM detect not only can improve the positive diagnosis rate of gynecological malignancies,has some clinical value,but also for gynecological benign and malignant tumors secondary diagnosis and differential diagnosis.
出处
《中国现代药物应用》
2013年第4期2-3,共2页
Chinese Journal of Modern Drug Application
